Company Overview
Snapshot
Founded in April 2000 by Shuki Yeshurun, NanoPass Technologies operates with 11–50 employees. The company has raised $14.1M across 6 funding rounds from 6 investors. In July 2024, NanoPass Technologies secured a $4M investment from Awz Ventures, signaling continued growth and innovation in intradermal delivery technology.
Business overview
NanoPass Technologies is at the forefront of healthcare innovation, specializing in intradermal delivery solutions. The company develops proprietary technology, including its MicronJetTM intradermal delivery product platform, to enhance therapeutic and medical aesthetic procedures. NanoPass Technologies serves the health tech and life sciences sectors, focusing on drug delivery and medical devices to provide precise, safe, and efficient medical solutions.
Strategic signal
In July 2024, NanoPass Technologies secured a $4M investment from Awz Ventures. This funding underscores investor confidence in the company's pioneering intradermal delivery technology and its potential to advance medical and aesthetic treatments, positioning NanoPass for further product development and market expansion.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant recent investment in NanoPass Technologies?
- In July 2024, NanoPass Technologies secured a $4M investment from Awz Ventures, signaling growth and innovation in its intradermal delivery technology.
- What is NanoPass Technologies' primary product platform?
- NanoPass Technologies' primary product platform is the MicronJetTM, which is designed for intradermal delivery in therapeutic and medical aesthetic procedures.
- When did NanoPass Technologies expand its product portfolio?
- In January 2026, NanoPass Technologies will officially launch MicronJet™ 800 during IMCAS World 2026, expanding its product portfolio to advance intradermal delivery.
- Which company licensed NanoPass Technologies' MicronJet device in November 2012?
- In November 2012, NanoPass Technologies granted a commercial license to Janssen Pharmaceuticals, Inc., for the use of its MicronJet device.
- What was a key partnership for NanoPass Technologies in September 2015?
- In September 2015, NanoPass Technologies partnered to supply its MicronJet600™ device to Immune Design for use in ZVex-based oncology immunotherapy products.